Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research SystemsfiledCriticalApplied Research Systems
Priority to TW94141979ApriorityCriticalpatent/TWI266801B/en
Publication of TW200619386ApublicationCriticalpatent/TW200619386A/en
Application grantedgrantedCritical
Publication of TWI266801BpublicationCriticalpatent/TWI266801B/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
PEG-IFN-beta conjugates, where a PEG moiety is covalently bound to Cys17 of human IFN-beta, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-beta.
Process for the production of conjugates containing orto ligating functional group from chelate complexes and joint antibodies or antibody fragments and the medical preparations containing thereof
Conjugates of metal complexes and oligonucleotides, which specifically bond to specific target structures, agents containing these conjugates, their use in nmr diagnosis as well as process for their production